Solventum (MEX:SOLV) Change In Payables And Accrued Expense: MXN309 Mil (TTM As of Mar. 2026)


MEX:SOLV Solventum Corp MEX:SOLV
23 GF Score
Price MXN1,300.00
! 6 Warning Signs
View Full Analysis

What is Solventum Change In Payables And Accrued Expense?

Solventum MEX:SOLV 23 Change In Payables And Accrued Expense is MXN309 Mil as of Mar. 2026. GuruFocus rates MEX:SOLV with a GF Score™ of 23/100. The stock has 6 warning signs investors should review.

Solventum's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2026 was MXN-4,111 Mil. It means Solventum's Accounts Payable & Accrued Expense declined by MXN4,111 Mil from Dec. 2025 to Mar. 2026 .

Solventum's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2025 was MXN2,449 Mil. It means Solventum's Accounts Payable & Accrued Expense increased by MXN2,449 Mil from Dec. 2024 to Dec. 2025 .

Solventum Change In Payables And Accrued Expense Historical Data

* Premium members only.

The historical data trend for Solventum's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Change In Payables And Accrued Expense Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Payables And Accrued Expense
Get a 7-Day Free Trial 1,394.95 487.40 4,192.64 -1,063.64 2,448.78

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,127.65 1,393.36 2,072.90 954.30 -4,111.46
MEX:SOLV
23GF Score
Solventum Corp MEX:SOLV
Change In Payables And Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN309 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Payables And Accrued Expense of MXN309 Mil mean?
Solventum (MEX:SOLV) has a Change In Payables And Accrued Expense of MXN309 Mil as of Mar. 2026. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Solventum and its competitors.
Is Solventum's Change In Payables And Accrued Expense too high?
Solventum's current Change In Payables And Accrued Expense is MXN309 Mil. Overall, Solventum has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Change In Payables And Accrued Expense compare to ALGN and COO?
Solventum's Change In Payables And Accrued Expense of MXN309 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Payables And Accrued Expense for a Medical Devices & Instruments company?
A good Change In Payables And Accrued Expense depends on the Medical Devices & Instruments industry context. However, Change In Payables And Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Payables And Accrued Expense mean?
A high Change In Payables And Accrued Expense can signal that a stock is expensive relative to its fundamentals. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Solventum and its competitors. Solventum's current Change In Payables And Accrued Expense is MXN309 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (MEX:SOLV) has a current Change In Payables And Accrued Expense of MXN309 Mil. The current Change In Payables And Accrued Expense is MXN309 Mil. Solventum's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Payables And Accrued Expense calculated?
Change In Payables And Accrued Expense is calculated from a company's financial statements. For Solventum (MEX:SOLV), the current Change In Payables And Accrued Expense is MXN309 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
23GF Score

Get the complete analysis for MEX:SOLV

Change In Payables And Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,300.00
Price